Reports Q4 revenue $56.75M, consensus $52.95M. “Our exceptional fourth quarter performance capped a year of significant growth for Cerus (CERS), positioning us well for 2025 and beyond. INTERCEPT double-digit product revenue growth in 2024 reflects the continued momentum of our platelets business and rising clinical demand for our IFC product, underscoring the expanding impact of our pathogen inactivation technology in transfusion medicine,” stated William “Obi” Greenman, Cerus’ president and chief executive officer.
Education
About Us
Working with TipRanks
Follow Us
1